Literature DB >> 29549060

Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays?

M Mikulska1, C Cordonnier2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29549060     DOI： 10.1016/j.cmi.2018.02.031

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  8 in total

Review 1.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

2.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

3.  Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Authors:  C Gudiol; A Albasanz-Puig; J Laporte-Amargós; N Pallarès; A Mussetti; I Ruiz-Camps; P Puerta-Alcalde; E Abdala; C Oltolini; M Akova; M Montejo; M Mikulska; P Martín-Dávila; F Herrera; O Gasch; L Drgona; H Paz Morales; A-S Brunel; E García; B Isler; W V Kern; I Morales; G Maestro-de la Calle; M Montero; S S Kanj; O R Sipahi; S Calik; I Márquez-Gómez; J I Marin; M Z R Gomes; P Hemmatti; R Araos; M Peghin; J L Del Pozo; L Yáñez; R Tilley; A Manzur; A Novo; J Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 4.  [Febrile neutropenia in pediatric and adolescent cancer patients].

Authors:  K Bochennek; A Simon; H-J Laws; A H Groll; T Lehrnbecher
Journal:  Monatsschr Kinderheilkd       Date:  2021-03-15       Impact factor: 0.416

Review 5.  Should serum biomarker monitoring replace primary antifungal chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer therapy? A PRO/CON debate.

Authors:  Thomas Harrison; David Partridge
Journal:  JAC Antimicrob Resist       Date:  2022-07-22

6.  Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey.

Authors:  Enrico Maria Trecarichi; Gabriele Giuliano; Chiara Cattaneo; Stelvio Ballanti; Marianna Criscuolo; Anna Candoni; Francesco Marchesi; Marica Laurino; Michelina Dargenio; Rosa Fanci; Mariagiovanna Cefalo; Mario Delia; Angelica Spolzino; Laura Maracci; Gianpaolo Nadali; Alessandro Busca; Maria Ilaria Del Principe; Rosa Daffini; Edoardo Simonetti; Giulia Dragonetti; Maria Elena Zannier; Livio Pagano; Mario Tumbarello
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

7.  Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Mark T Drayson; Stella Bowcock; Tim Planche; Gulnaz Iqbal; Guy Pratt; Kwee Yong; Jill Wood; Kerry Raynes; Helen Higgins; Bryony Dawkins; David Meads; Claire T Hulme; Irene Monahan; Kamaraj Karunanithi; Helen Dignum; Edward Belsham; Jeff Neilson; Beth Harrison; Anand Lokare; Gavin Campbell; Michael Hamblin; Peter Hawkey; Anna C Whittaker; Eric Low; Janet A Dunn
Journal:  Lancet Oncol       Date:  2019-10-23       Impact factor: 41.316

8. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.